Releases
ASLN
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Aslan Pharms (ASLN) stock and general news. This information may help you make smarter investment decisions.
About ASLN
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. The Company's ASLAN004 is a fully human monoclonal antibody targeting the IL-13 receptor a1 subunit (IL-13Ra1). By targeting IL-13Ra1, which forms the Type II receptor complex with IL-4Ra, ASLAN004 inhibits signaling of both interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheeze and cough.